Download Full Text (560 KB)
- New Drug Control Symptoms of Myeloproliferative Disorders and Improve Quality of Life for Patients: Recent clinical trials have demonstrated that a new class of drugs can effectively treat myeloproliferative disorders
- Compass: Metastatic Melanoma: Experimental tratments could be preferable to tandard therapies for metastatic melanoma
- HOUS CALL: Breast Awareness: Guidelines recommend breast awareness rather than formal self-exams
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
The University of Texas MD Anderson Cancer Center
Verstovek, Srdan; Woodman, Scott; Kim, Kevin; Davies, Michael; Hwu, Patrick; Myeloproliferative Disorders; Philadelphia Chromosome; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polycythemia Vera; Thrombocythemia, Essential; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocytosis; Hypereosinophilic Syndrome; Mastocytosis, Systemic; Prednisone; Hydroxyurea; Imatinib Mesylate; Dasatinib; Pyrimidines; Janus Kinase 2; ruxolitinib; Melanoma; Melanoma -- secondary; Antineoplastic Agents; Dacarbazine; Drug Resistance, Neoplasm; Interleukin-2; Interferon alpha-2; BRAF protein, human; Vemurafenib; Ipilimumab; Antibodies, Monoclonal; Cancer Vaccines; Immunotherapy, Adoptive; Health Knowledge, Attitudes, Practice; Breast Self-Examination.
Tutt, Bryan and Hosemann, Sunni, "OncoLog, Volume 56, Number 01, January 2011" (2011). OncoLog MD Anderson's Report to Physicians (All issues). 211.
Conditions Governing Access